Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y.

Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006.

2.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y.

Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6.

3.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA.

J Biol Chem. 2013 Feb 22;288(8):5718-31. doi: 10.1074/jbc.M112.379446. Epub 2012 Dec 28.

4.

STAT protein complexes activated by interferon-gamma and gp130 signaling molecules differ in their sequence preferences and transcriptional induction properties.

Lamb P, Seidel HM, Haslam J, Milocco L, Kessler LV, Stein RB, Rosen J.

Nucleic Acids Res. 1995 Aug 25;23(16):3283-9.

5.

Rapid activation of proteins that interact with the interferon gamma activation site in response to multiple cytokines.

Lamb P, Kessler LV, Suto C, Levy DE, Seidel HM, Stein RB, Rosen J.

Blood. 1994 Apr 15;83(8):2063-71.

PMID:
8161777

Supplemental Content

Loading ...
Support Center